Pivotal Trial For GSK/Xenoport’s Sustained-Release Restless Legs Drug Supports Efficacy
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of the drug could reach $958 million in 2013, analyst predicts, including RLS and neuropathic pain indications.
You may also be interested in...
Generic Requip Cleared For RLS
Teva, Mylan, Roxane and Par will market ropinirole for Restless Legs Syndrome; Parkinson's patent expires this month, too.
Generic Requip Cleared For RLS
Teva, Mylan, Roxane and Par will market ropinirole for Restless Legs Syndrome; Parkinson's patent expires this month, too.
GSK, XenoPort Will Include Two-Dose Data In NDA For Restless Legs Drug
Positive efficacy with 600 mg a "surprise," XenoPort CEO says.